Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2011-08-23
2011-08-23
Chu, Yong (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S538000, C514S620000, C549S417000, C560S042000, C564S164000
Reexamination Certificate
active
08003689
ABSTRACT:
This invention provides metabolites of SARM compounds including inter alia glucuronidated metabolites and uses thereof in treating a variety of diseases or conditions in a subject, including, inter alia, muscle wasting disease and/or disorder, a bone related disease and/or disorder, metabolic syndrome, diabetes and associated diseases, and others.
REFERENCES:
patent: 3239345 (1966-03-01), Hodge et al.
patent: 3865801 (1975-02-01), Chiba et al.
patent: 4036979 (1977-07-01), Asato
patent: 4411890 (1983-10-01), Momany
patent: 5179080 (1993-01-01), Rothkopf
patent: 5441868 (1995-08-01), Lin et al.
patent: 5547933 (1996-08-01), Lin et al.
patent: 5552412 (1996-09-01), Cameron et al.
patent: 5618698 (1997-04-01), Lin et al.
patent: 5621080 (1997-04-01), Lin et al.
patent: 6019957 (2000-02-01), Miller et al.
patent: 2003/0086848 (2003-05-01), Saccomanno
patent: 2004/0214790 (2004-10-01), Borgens
patent: 2005/0038110 (2005-02-01), Steiner et al.
patent: 2006/0035966 (2006-02-01), Dalton et al.
patent: 2007/0161608 (2007-07-01), Dalton et al.
patent: 0 668 351 (1990-10-01), None
patent: WO 89/07110 (1989-08-01), None
patent: WO 89/07111 (1989-08-01), None
patent: WO 91/05867 (1991-05-01), None
patent: WO 93/04081 (1993-03-01), None
patent: WO 01/68603 (2001-09-01), None
patent: WO 2005/113565 (2005-10-01), None
patent: WO 2005113565 (2005-12-01), None
U.S. Appl. No. 09/519,079, filed Mar. 6, 2000, Robl et al.
Matsumoto. “Hormonal therapy of male hypogonadism.” Endocrinol. Met. Clin. N. Am. 23:857-75 (1994).
Zhou et al. “Specificity of ligand-dependent androgen receptor stabilization: receptor domain interactions influence ligand dissociation and receptor stability.” Molec. Endocrinol. 9:208-18 (1995).
Sundaram et al. “7a-Methyl-Nortestosterone (MENT): The Optimal Androgen for Male Contraception” (Annals of Medicine 25: 199-205, (1993).
Thevis et al. “Screening for metabolically stable aryl-propionamide-derived selective androgen receptor modulators for doping control purposes” Rapid Communications in Mass Spectrometry vol. 20, Issue 5, pp. 870-876, Mar. 15, 2006.
Thevis et al. “Screening for 2-quinolinone-derived selective androgen receptor agonists in doping control analysis” Rapid Commun Mass Spectrom. ;21(21):3477-86. (2007).
Thevis et al. “New drugs and methods of doping and manipulation” Drug Discovery Today vol. 13, Issues 1-2, pp. 59-66 , Jan. 2008.
Kuuranne et al. “Aryl-propionamide-derived selective androgen receptor modulators: liquid chromatography-tandem mass spectrometry characterization of the in vitro synthesized metabolites for doping control purposes” Drug Metab Dispos. 36(3):571-81, Mar. 2008.
Singh et al. “Androgens stimulate myogenic differentiation and inhibit adipogenesis in C3H 10T1/2 pluripotent cells through an androgen receptor-mediated pathway” Endocrinology. 144(11):5081-8, Nov. 2003.
Langer. “New methods of drug delivery” Science 28: vol. 249 No. 4976 pp. 1527-1533, Sep. 1990.
Treat et al. “In Liposomes in the Therapy of Infectious Disease and Cancer” Lopez-Berestein and Fidler (eds.), Liss, New York, pp. 353-365 (1989).
Lopez-Berestein in Liposomes in the Therapy of Infectious Disease and Cancer, Lopez-Berestein and Fidler (eds.), Liss, New York, pp. 317-327. (1984).
Sefton, CRC Crit. Ref. Biomed. Eng. 14:201 (1987).
Buchwald et al. “Long-term, continuous intravenous heparin administration by an implantable infusion pump in ambulatory patients with recurrent venous thrombosis.” Surgery 88:507 (1980).
Saudek et al.“A preliminary trial of the programmable implantable medication system for insulin delivery.” N. Engl. J. Med. 321:574 (1989).
Goodson, in Medical Applications of Controlled Release, supra, vol. 2, pp. 115-138 (1984).
Abuchowski et al. “Immunosuppressive properties and circulating life of Achromobacter glutaminase-asparaginase covalently attached to polyethylene glycol in man” Cancer Treat Rep. 65(11-12):1077-81. Nov.-Dec. 1981.
Katre et al. “Chemical modification of recombinant interleukin 2 by polyethylene glycol increases its potency in the murine Meth A sarcoma model” Proc Natl Acad Sci U S A. 84(6):1487-91. Mar. 1987.
Edwards et al. “Nonsteroidal androgen receptor agonists based on 4-(trifluoromethyl)-2H-pyrano[3,2-g]quinolin-2-one” Bioorg. Med. Chem. Lett., 9: 1003-1008, (1999).
Hamann et al. “Discovery of a potent, orally active nonsteroidal androgen receptor agonist: 4-ethyl-1,2,3,4-tetrahydro-6-(trifluoromethyl)-8-pyridono[5,6-g]-quinoline (LG121071)” J. Med. Chem., 42:210-212, (1999).
Roymans et al. Expression and Induction Potential of Cytochromes P450 in Human Cryopreserved Hepatocytes Drug Metab. Dispos., 33(7), 1004-1016, (2005).
International Search Report of Application No. PCT/US 09/47892 Date of Mailing Sep. 16, 2009.
Chu Yong
Cohen Mark S.
GTx, Inc.
Pearl Cohen Zedek Latzer LLP
LandOfFree
Metabolites of selective androgen receptor modulators and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Metabolites of selective androgen receptor modulators and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Metabolites of selective androgen receptor modulators and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2754349